Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
0.3949
Dollar change
+0.0485
Percentage change
14.00
%
Index- P/E- EPS (ttm)-98.35 Insider Own0.15% Shs Outstand- Perf Week17.95%
Market Cap1.16M Forward P/E- EPS next Y-4.97 Insider Trans0.00% Shs Float2.92M Perf Month-24.00%
Income-8.28M PEG- EPS next Q-0.73 Inst Own2.49% Short Float4.92% Perf Quarter-75.62%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.19 Perf Half Y-94.57%
Book/sh5.88 P/B0.07 EPS next Y- ROA-130.64% Short Interest0.14M Perf Year-99.72%
Cash/sh2.17 P/C0.18 EPS next 5Y- ROE-189.06% 52W Range0.30 - 154.70 Perf YTD-98.87%
Dividend Est.- P/FCF- EPS past 5Y26.64% ROI-171.92% 52W High-99.74% Beta-1.74
Dividend TTM- Quick Ratio3.11 Sales past 5Y-20.00% Gross Margin- 52W Low30.98% ATR (14)0.07
Dividend Ex-Date- Current Ratio3.11 EPS Y/Y TTM92.39% Oper. Margin0.00% RSI (14)39.85 Volatility15.91% 14.33%
Employees4 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.00
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q98.06% Payout- Rel Volume13.06 Prev Close0.35
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 14 BMO Avg Volume767.62K Price0.39
SMA20-9.11% SMA50-19.84% SMA200-95.24% Trades Volume10,023,040 Change14.00%
Oct-07-24 08:30AM
Sep-30-24 08:30AM
Sep-26-24 08:00AM
Sep-25-24 08:45AM
Sep-18-24 09:00AM
08:45AM Loading…
Sep-05-24 08:45AM
Sep-04-24 08:45AM
Aug-14-24 08:05AM
Jul-15-24 09:05AM
Jul-11-24 09:20AM
Jul-08-24 09:05AM
Jul-02-24 09:05AM
Jul-01-24 08:45AM
Jun-28-24 04:05PM
Jun-27-24 09:00AM
08:00AM Loading…
08:00AM
Jun-26-24 08:23AM
07:41AM
Jun-24-24 07:16AM
Jun-17-24 08:00AM
Jun-14-24 08:05AM
Jun-12-24 04:15PM
Jun-11-24 09:00AM
Jun-10-24 08:00AM
May-23-24 10:30AM
May-22-24 09:15AM
May-21-24 08:35AM
May-20-24 08:45AM
May-14-24 09:05AM
May-13-24 10:54AM
08:00AM Loading…
08:00AM
Apr-29-24 08:45AM
Apr-25-24 09:15AM
Apr-16-24 08:35AM
Apr-08-24 08:35AM
Apr-01-24 07:35AM
Mar-28-24 09:00AM
Mar-14-24 08:45AM
Mar-04-24 08:30AM
Feb-02-24 08:55AM
08:00AM
Jan-26-24 08:05AM
Dec-06-23 01:47PM
Dec-05-23 09:05AM
Nov-27-23 08:35AM
Nov-15-23 08:05AM
Oct-31-23 08:45AM
Oct-19-23 08:45AM
Oct-18-23 10:00AM
Oct-17-23 08:35AM
Oct-11-23 09:05AM
Oct-05-23 08:45AM
Sep-29-23 09:00AM
Sep-06-23 09:05AM
Sep-01-23 09:15AM
Aug-29-23 11:06AM
Aug-25-23 09:00AM
Aug-23-23 09:00AM
Aug-16-23 12:00PM
Aug-14-23 08:05AM
Aug-07-23 08:35AM
Aug-03-23 08:30AM
Jul-26-23 11:15AM
Jul-24-23 09:00AM
Jul-05-23 08:45AM
Jun-27-23 08:45AM
Jun-15-23 08:45AM
Jun-13-23 08:35AM
May-22-23 08:45AM
Apr-27-23 09:05AM
Apr-25-23 08:45AM
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.